JPH08208622A - 置換された1h−イミダゾール - Google Patents

置換された1h−イミダゾール

Info

Publication number
JPH08208622A
JPH08208622A JP7324502A JP32450295A JPH08208622A JP H08208622 A JPH08208622 A JP H08208622A JP 7324502 A JP7324502 A JP 7324502A JP 32450295 A JP32450295 A JP 32450295A JP H08208622 A JPH08208622 A JP H08208622A
Authority
JP
Japan
Prior art keywords
imidazole
tetrahydro
naphthalenyl
substituted
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP7324502A
Other languages
English (en)
Japanese (ja)
Inventor
Jean-Pierre Geerts
− ピエール ジェール ジャン
Genevieve Motte
モッテ ジュネビエブ
Edmond Differding
ディフェルディン エドモン
Jean-Pierre Henichart
− ピエール アンシャール ジャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB SA filed Critical UCB SA
Publication of JPH08208622A publication Critical patent/JPH08208622A/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP7324502A 1994-12-14 1995-12-13 置換された1h−イミダゾール Pending JPH08208622A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9425211.1A GB9425211D0 (en) 1994-12-14 1994-12-14 Substituted 1H-imidazoles
GB94252111 1994-12-14

Publications (1)

Publication Number Publication Date
JPH08208622A true JPH08208622A (ja) 1996-08-13

Family

ID=10765918

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7324502A Pending JPH08208622A (ja) 1994-12-14 1995-12-13 置換された1h−イミダゾール

Country Status (26)

Country Link
US (1) US5658938A (enExample)
EP (1) EP0717037A1 (enExample)
JP (1) JPH08208622A (enExample)
KR (1) KR960022474A (enExample)
CN (1) CN1054376C (enExample)
AR (1) AR002257A1 (enExample)
AU (1) AU693614B2 (enExample)
BG (1) BG63043B1 (enExample)
BR (1) BR9505815A (enExample)
CA (1) CA2165133A1 (enExample)
CZ (1) CZ327195A3 (enExample)
EE (1) EE9500064A (enExample)
FI (1) FI955927L (enExample)
GB (1) GB9425211D0 (enExample)
HU (1) HUT73980A (enExample)
IL (1) IL116325A (enExample)
IS (1) IS4311A (enExample)
MX (1) MX9505063A (enExample)
NO (1) NO305316B1 (enExample)
NZ (1) NZ280646A (enExample)
PL (1) PL311736A1 (enExample)
RO (1) RO113346B1 (enExample)
RU (1) RU2156239C2 (enExample)
SK (1) SK155095A3 (enExample)
TW (1) TW303362B (enExample)
ZA (1) ZA9510554B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005523925A (ja) * 2002-04-29 2005-08-11 エフ エム シー コーポレーション 農薬用ヘテロ環状化合物
JP2009524618A (ja) * 2006-01-27 2009-07-02 エフ.ホフマン−ラ ロシュ アーゲー Cns障害の処置における2−イミダゾールの使用
JP2011506284A (ja) * 2007-12-05 2011-03-03 グリンデクス,ア ジョイント ストック カンパニー 5−(2−エチルジヒドロ−1h−インデン−2−イル)−1h−イミダゾール及びその塩の調製方法
JP2019508469A (ja) * 2016-03-17 2019-03-28 エフ エム シー コーポレーションFmc Corporation S−エナンチオマーのラセミ体への変換方法

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
GB9520150D0 (en) * 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
ZA981080B (en) 1997-02-11 1998-08-12 Warner Lambert Co Bicyclic inhibitors of protein farnesyl transferase
US20030073850A1 (en) * 1998-08-07 2003-04-17 Altenbach Robert J. 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use
US6503935B1 (en) 1998-08-07 2003-01-07 Abbott Laboratories Imidazoles and related compounds as α1A agonists
US6388090B2 (en) 2000-01-14 2002-05-14 Orion Corporation Imidazole derivatives
IL152401A0 (en) 2000-05-08 2003-05-29 Orion Corp New polycyclic indanylimidazoles with alpha2 adrenergic activity
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
FI20022007A0 (fi) * 2002-11-08 2002-11-08 Juvantia Pharma Ltd Oy Oromukosaalinen valmiste ja menetelmä sen valmistamiseksi
FI20022159A0 (fi) * 2002-12-05 2002-12-05 Orion Corp Uusia farmaseuttisia yhdisteitä
WO2008046756A1 (en) * 2006-10-19 2008-04-24 F. Hoffmann-La Roche Ag Aminomethyl-2-imidazoles with affinity with the trace amine associated receptors
CA2666762C (en) * 2006-10-19 2014-12-30 F. Hoffmann-La Roche Ag Aminomethyl-4-imidazoles
EP2086959B1 (en) * 2006-11-02 2011-11-16 F. Hoffmann-La Roche AG Substituted 2-imidazoles as modulators of the trace amine associated receptors
MX2009005047A (es) * 2006-11-16 2009-05-25 Hoffmann La Roche 4-imidazoles sustituidos.
MX2009005920A (es) * 2006-12-13 2009-06-16 Hoffmann La Roche Nuevos 2-imidazoles como ligandos para receptores asociados con trazas de amina.
US20080146523A1 (en) 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
MX2009008255A (es) * 2007-02-02 2009-08-12 Hoffmann La Roche Nuevas 2-aminooxazolinas como ligandos taar1.
CN101702905A (zh) * 2007-02-13 2010-05-05 先灵公司 功能选择性α2C肾上腺素能受体激动剂
JP2010518161A (ja) * 2007-02-13 2010-05-27 シェーリング コーポレイション 機能選択性α2Cアドレナリン受容体アゴニストとしてのクロマン誘導体および類似体
CA2678072A1 (en) * 2007-02-13 2008-08-21 Schering Corporation Functionally selective alpha2c adrenoreceptor agonists
KR101222412B1 (ko) * 2007-02-15 2013-01-15 에프. 호프만-라 로슈 아게 Taar1 리간드로서의 2-아미노옥사졸린
CN101687812A (zh) 2007-07-02 2010-03-31 弗·哈夫曼-拉罗切有限公司 对痕量胺相关受体(taar)具有良好亲和性的2-咪唑啉化合物
WO2009003867A1 (en) * 2007-07-03 2009-01-08 F. Hoffmann-La Roche Ag 4-imidazolines and their use as antidepressants
WO2009016048A1 (en) * 2007-07-27 2009-02-05 F. Hoffmann-La Roche Ag 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as taar-ligands
CN101765425A (zh) * 2007-08-02 2010-06-30 弗·哈夫曼-拉罗切有限公司 苯甲酰胺衍生物用于治疗cns障碍的用途
BRPI0814758A2 (pt) * 2007-08-03 2015-03-03 Hoffmann La Roche Piridinacarboxamida e derivados de benzamida como ligantes taar1
EP2257546B1 (en) 2008-02-21 2012-08-15 Merck Sharp & Dohme Corp. Functionally selective alpha2c adrenoreceptor agonists
US8242153B2 (en) * 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
CN102083805A (zh) * 2008-07-24 2011-06-01 弗·哈夫曼-拉罗切有限公司 4,5-二氢-唑-2-基衍生物
WO2010017120A1 (en) * 2008-08-04 2010-02-11 Schering Corporation Cyclopropylchromene derivatives as modulators of the alpha-2c receptor
WO2010042473A1 (en) 2008-10-07 2010-04-15 Schering Corporation Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators
US20100311798A1 (en) * 2009-06-05 2010-12-09 Decoret Guillaume 2-aminooxazolines as taar1 ligands
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US8673950B2 (en) 2010-11-02 2014-03-18 Hoffmann-Laroche Inc. Dihydrooxazol-2-amine derivatives
US8802673B2 (en) 2011-03-24 2014-08-12 Hoffmann-La Roche Inc Heterocyclic amine derivatives
US9073911B2 (en) 2011-06-09 2015-07-07 Hoffmann-La Roche Inc. Pyrazole derivatives
US9029370B2 (en) 2011-06-10 2015-05-12 Hoffmann-La Roche Inc. Substituted benzamide derivatives
RU2621050C2 (ru) 2012-01-12 2017-05-31 Ф. Хоффманн-Ля Рош Аг Гетероциклические производные в качестве рецепторов, ассоциированных со следовыми аминами (taars)
NO2895477T3 (enExample) 2012-09-14 2018-03-31
CA2879176C (en) * 2012-09-17 2020-10-27 F.Hoffmann-La Roche Ag Triazole carboxamide derivatives
WO2015165085A1 (en) 2014-04-30 2015-11-05 F.Hoffmann-La Roche Ag Morpholin-pyridine derivatives
CA2954098A1 (en) 2014-08-27 2016-03-03 F. Hoffmann-La Roche Ag Substituted azetidine derivatives as taar ligands
MX2016016190A (es) 2014-08-27 2017-03-08 Hoffmann La Roche Derivados de pirazino[2,1-a]isoquinolina sustituida para el tratamiento de trastornos del sistema nervioso central.
JP6814814B2 (ja) 2016-03-17 2021-01-20 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Taarのアゴニストとしての活性を有する5−エチル−4−メチル−ピラゾール−3−カルボキサミド誘導体
CN116496261B (zh) * 2023-03-09 2025-06-27 中国人民解放军军事科学院军事医学研究院 4-(1h)-咪唑类衍生物及其医药用途
CN118684628B (zh) * 2024-05-20 2025-06-17 中国人民解放军军事科学院军事医学研究院 取代二氢茚基咪唑类化合物及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6048972A (ja) * 1983-08-25 1985-03-16 Dai Ichi Seiyaku Co Ltd テトラヒドロナフタレン誘導体
GB2167408B (en) * 1984-11-23 1988-05-25 Farmos Oy Substituted imidazole derivatives and their preparation and use
GB8626287D0 (en) * 1986-11-04 1986-12-03 Ucb Sa Substituted 1h-imidazoles
GB2206880B (en) * 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
US5151526A (en) * 1990-10-11 1992-09-29 The United States Of America As Represented By The Secretary Of The Army 4-[1-(1-naphthalenyl)ethyl]-1H-imidazole, method of making and use as an anesthetic
JPH04210680A (ja) * 1990-12-01 1992-07-31 Nissan Chem Ind Ltd イミダゾール誘導体および植物生長調節剤
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005523925A (ja) * 2002-04-29 2005-08-11 エフ エム シー コーポレーション 農薬用ヘテロ環状化合物
JP2009524618A (ja) * 2006-01-27 2009-07-02 エフ.ホフマン−ラ ロシュ アーゲー Cns障害の処置における2−イミダゾールの使用
JP2011506284A (ja) * 2007-12-05 2011-03-03 グリンデクス,ア ジョイント ストック カンパニー 5−(2−エチルジヒドロ−1h−インデン−2−イル)−1h−イミダゾール及びその塩の調製方法
JP2019508469A (ja) * 2016-03-17 2019-03-28 エフ エム シー コーポレーションFmc Corporation S−エナンチオマーのラセミ体への変換方法

Also Published As

Publication number Publication date
AU4036895A (en) 1996-06-20
NO955034D0 (no) 1995-12-12
FI955927A0 (fi) 1995-12-11
FI955927A7 (fi) 1996-06-15
HUT73980A (en) 1996-10-28
RU2156239C2 (ru) 2000-09-20
SK155095A3 (en) 1997-02-05
KR960022474A (ko) 1996-07-18
CN1133837A (zh) 1996-10-23
NZ280646A (en) 1996-08-27
IL116325A (en) 1999-10-28
BR9505815A (pt) 1998-01-06
GB9425211D0 (en) 1995-02-15
AU693614B2 (en) 1998-07-02
EE9500064A (et) 1996-06-17
MX9505063A (es) 1997-01-31
NO955034L (no) 1996-06-17
US5658938A (en) 1997-08-19
ZA9510554B (en) 1996-06-13
PL311736A1 (en) 1996-06-24
TW303362B (enExample) 1997-04-21
CA2165133A1 (en) 1996-06-15
CN1054376C (zh) 2000-07-12
EP0717037A1 (fr) 1996-06-19
BG100208A (bg) 1996-07-31
AR002257A1 (es) 1998-03-11
RO113346B1 (ro) 1998-06-30
IS4311A (is) 1996-06-15
HU9503549D0 (en) 1996-02-28
FI955927L (fi) 1996-06-15
NO305316B1 (no) 1999-05-10
BG63043B1 (bg) 2001-02-28
CZ327195A3 (en) 1996-07-17
IL116325A0 (en) 1996-03-31

Similar Documents

Publication Publication Date Title
JPH08208622A (ja) 置換された1h−イミダゾール
CA1237723A (en) Antidepressant 1,2,4-triazolone compounds
JP2000507914A (ja) α2受容体活性に親和性を有するイミダゾール誘導体
JPS62281858A (ja) ピペリジン誘導体及びその類縁誘導体
CA2172986A1 (fr) Tetrahydropyridine-(ou 4-hydroxypiperidine) alkylazoles ayant une activite pour les recepteurs sigma et/ou 5ht1a
JPH054391B2 (enExample)
Alabaster et al. 2 (1H)-Quinolinones with cardiac stimulant activity. 2. Synthesis and biological activities of 6-(N-linked, five-membered heteroaryl) derivatives
KR950000779B1 (ko) 신경안정적 또는 정신안정적 활성을 가진 피리미디닐-피페라지닐-알킬아졸 유도체
JPH06511239A (ja) ヘテロアルコキシベンズアゼピン類
JP2840288B2 (ja) 置換1―(1h―イミダゾール―4―イル)アルキル―ベンズアミド
JP3165935B2 (ja) 3(2h)−ピリダジノン誘導体、その製造法、及びそれを含有する製剤組成物
CN101827828B (zh) 作为5-羟色胺能调节剂的1,2,4-三唑衍生物
EP0306440A2 (en) 1-(4-substituted phenyl)-1H-imidazoles as cardiovascular agents
EP0381235A2 (en) Pyrrolidine compound and pharmaceutical use
EP0220735B1 (en) 3(2h)-pyridazinone derivatives, a process and intermediates for preparing them and medicaments containing them and/or other 3(2h)-pyridazinone derivatives
US4386091A (en) 2-Phenoxyalkyl-1,2,4-triazol-3-one antidepressants
JP2002507983A (ja) (1h−イミダゾール−4−イル)ピペリジン誘導体、それらの製造およびそれらの治療における応用
US6248907B1 (en) N-([1,4]benzodioxan-2-ylmethyl)-N-(3-chloro-1-propyl)-amine
HU202232B (en) Process for producing 3-piperidinyl-indazol derivatives and pharmaceutical compositions of antihypertensive activity containing them as active components
US4105768A (en) Hypotensive substituted 1,2,4-triazoles
JPS6178767A (ja) 二環式ラクタム、その製造方法及びそれを含有する調製剤
US4022905A (en) Benzylidene hydrazino-1,2,4-triazoles, pharmaceuticals therewith, and method of use
JPH07165729A (ja) 新規なベンゾスピロアルケン誘導体、それらの製造法 及びそれら誘導体を含有する製剤組成物
JPH06293732A (ja) ピペリジン誘導体及びその類縁誘導体
HU211693A9 (hu) Új 5H-benzodiazepin-származék, ilyen hatóanyagot tartalmazó gyógyászati készítmények és eljárás a hatóanyag és a készítmények előállítására